Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration or FDA granted Breakthrough Therapy designation for Xalkori, or crizotinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy.